Abiraterone Risk Higher in Prostate Cancer Patients Who Have CVD Abiraterone Risk Higher in Prostate Cancer Patients Who Have CVD
A new analysis finds that men with prostate cancer treated with abiraterone acetate have a significantly higher mortality if they also have preexisting cardiovascular disease.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Heart | Hematology | Prostate Cancer